Your session is about to expire
← Back to Search
ASA for Ovarian Cancer Prevention
Study Summary
This trial will investigate whether taking ASA reduces the risk of developing ovarian cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had cancer before, but it was either skin cancer, cervical cancer treated without surgery, breast cancer treated to cure, or any cancer cured over 5 years ago.You are allergic to aspirin or have a history of asthma caused by aspirin or similar drugs like ibuprofen.I have kidney, liver problems, or heart failure.I regularly take aspirin or NSAIDs daily for a chronic condition.I plan to have surgery to lower my cancer risk within 6 months to 2 years after joining the study.I am 18 years old or older.I am currently taking blood thinners or anti-platelet medications.I have been treated with a PARP-inhibitor like olaparib.I have a condition that causes me to bleed easily.I currently have an active peptic ulcer.I am fully active or can carry out light work.I can start the trial treatment within 2 days after being chosen.I can and am willing to fill out a questionnaire in English or French.I have a confirmed genetic mutation in BRCA1/2.I have had both of my fallopian tubes surgically removed.
- Group 1: Placebo
- Group 2: Acetylsalicylic Acid (ASA)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you name a few of the Canadian medical facilities conducting this trial?
"North York General Hospital in Toronto, CIUSSS de l'Estrie - Centre hospitalier in Sherbrooke and Hotel-Dieu de Quebec in Quebec City are among the 12 medical sites offering this trial along with other centres."
Is this investigation pioneering a new approach to treatment?
"Ever since the initial clinical trial for Acetylsalicylic Acid (ASA) was sponsored by Abbott in 2005, involving 15480 patients, it has moved through drug approval phases and is now in Phase 4. As of today, 169 studies are actively taking place across 57 different nations and 1398 urban centres."
Has Acetylsalicylic Acid (ASA) been given the green light by the FDA?
"Our team at Power assigns Acetylsalicylic Acid a safety rating of 2, since Phase 2 trials have provided some evidence demonstrating its security but not efficacy."
Are there still opportunities for individuals to take part in this investigation?
"Affirmative. Clinicaltrials.gov has established that this analysis, which was initially posted on April 6th 2018, is actively recruiting participants. 414 people need to be enrolled from 12 different centres."
To what end is Acetylsalicylic Acid (ASA) commonly employed?
"Acetylsalicylic Acid (ASA) is typically indicated for percutaneous coronary intervention (pci). But it can also be prescribed to assist with dental procedures, reduce inflammation, and alleviate neck pain."
What other investigations have been conducted featuring Acetylsalicylic Acid (ASA)?
"Acetylsalicylic Acid (ASA) was first researched in 2005 by the Clinical Trial Service Unit, NDPH at University of Oxford. Since then, 18757 studies have been completed and there are currently 168 medical trials actively seeking participants. Of these trails, a significant portion is being hosted out of Toronto and Quebec."
How many participants are actively engaged with this trial?
"To satisfy the study's enrollment requirements, Apotex Inc. must enlist a total of 414 compliant volunteers. In order to do so, they will be running clinical trials at North York General Hospital in Toronto and CIUSSS de l'Estrie - Centre hospitalier in Sherbrooke, Alberta."
Share this study with friends
Copy Link
Messenger